Key facts about Vorinostat
What dosages is Vorinostat available in?
Vorinostat is available as a 100 mg oral capsule.
What is Vorinostat used for?
Vorinostat is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous Tcell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
How does Vorinostat work?
Vorinostat is a histone deacetylase (HDAC) inhibitor that treats lymphoma.
How do I take Vorinostat?
Vorinostat is typically taken as 400 mg orally once daily with food. If patient is intolerant to therapy, reduce the dose to 300 mg orally once daily with food. If necessary, reduce the dose further to300 mg once daily with food for 5 consecutive days each week. Reduce dose in patients with mild or moderate hepatic impairment.
Is it safe for me to take Vorinostat?
Vorinostat is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.
Vorinostat Common Side Effects
Common side effects of Vorinostat:
- Diarrhea
- Fatigue
- Nausea
- Thrombocytopenia
- Anorexia
- Foul or metallic taste
Vorinostat Serious Side Effects
Serious side effects are rare with Vorinostat.
Effects of other drugs, drug classes and over-the-counter products on Vorinostat
The following medications may interact with Vorinostat:
- Coumarin-derivative anticoagulants: Prolongation of prothrombin time and International Normalized Ratio (INR) have been observed with concomitant use. Monitor INR frequently
Who makes Vorinostat?
Various FDA-approved generic manufacturers
Is Vorinostat safe in pregnancy?
vorinostatBased on its mechanism of action and findings from animal studies, Vorinostat can cause fetal harm
when administered to a pregnant woman. Females should have pregnancy testing done within 7 days prior to initiating therapy
with Vorinostat. Females should use effective contraception during treatment with Vorinostat and for at least 6 months after the last dose. Males with female partners of reproductive potential to use effective contraception and to avoid
fathering a child during treatment with Vorinostat and for at least 3 months after the last dose.
